Critical Reviews in Oncology / Hematology
Volume 74, Issue 3 , Pages 193-202 , June 2010

Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab

,Accepted 23 July 2009.

References 

  1. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–592
  2. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004;350:2050–2059
  3. O’Connell MJ. Current status of adjuvant therapy for colorectal cancer. Oncology (Williston Park). 2004;18:751–755
  4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  5. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–345
  6. Bengtsson G, Carlsson G, Hafström L, Jönsson PE. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg. 1981;141:586–589
  7. de Brauw LM, van de Velde CJ, Bouwhuis-Hoogerwerf ML, Zwaveling A. Diagnostic evaluation and survival analysis of colorectal cancer patients with liver metastases. J Surg Oncol. 1987;34:81–86
  8. Gaffe BM, Donegan WL, Watson F, Sprat JS. Factor influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet. 1969;127:1–11
  9. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–237
  10. Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: panitumumab (Vectibix). Oncologist. 2007;12:577–583
  11. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19:6550–6565
  12. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127–137
  13. Scaltriti M, Baselga J. The epidermal growth receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12:5268–5272
  14. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14:737–744
  15. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792
  16. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171–2177
  17. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201–1208
  18. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2311–2319
  19. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metatatic colorectal cancer: the Crystal trial. J Clin Oncol. 2007;25:[abstract 4000]
  20. Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer: OPUS, a randomized phase II study. J Clin Oncol. 2007;25:[abstract 4035]
  21. Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040–2048
  22. Ryan Q, Ibrahim A, Cohen MH, et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist. 2008;13:1114–1119
  23. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149–2158
  24. Gridelli C, Bareschino MA, Schettino C, et al. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist. 2007;12:840–849
  25. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–1966
  26. Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs. 2007;18:7–15
  27. Freeman D, McDorman K, Bush T, et al. Mono and combination-therapeutic activity of panitumumab (ABX-EGF) on human A431 epidermoid and HT-29 colon carcinoma xenografts; correlation with pharmacodynamic parameters. Proc Amer Assoc Cancer Res. 2004;27–31
  28. Mendez MJ, Green LL, Corvalan JR, et al. Functional transplant of magabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet. 1997;15:146–156
  29. Fan Z, Baselga J, Masui H, Maendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993;53:4637–4642
  30. Yang XD, Jia XC, Corvalan JR, et al. Erradication of established tumors by a fully human monoclonal to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 1999;59:1236–1243
  31. Jia XC, Corvalan JRF, Zhang L. Inhibition of vascular endothelial cell growth factor and interleukin-8 production in tumor and endothelial cell lines by a fully human monoclonal antibody to epidermal groth factor receptor. Proc Amer Assoc Cancer Res. 2000;290
  32. Yang XD, Corvalan JRF, Wang P. Inhibition of human cancer growth by ABX-EGF, a fully human anti-EGF receptor monoclonal antibody. Proc Am Assoc Cancer Res. 2000;530
  33. Lynch DH, Yang XD. Therapeutic potential of ABX-EGF: a fully antiepidermal growth factor reeptor monoclonal antibody for cancer treatment. Semin Oncol. 2002;29:47–50
  34. Arends R, Yang B, Schwab G, et al. Flexible dosing schedules of panitumumab in cancer patients. J Clin Oncol. 2005;23:[abstract 3089]
  35. Weiner LM, Belldegrun A, Rowinsky E, et al. Updated results from a dose and schedule study of Panitumumab monotherapy in patients with advanced solid malignancies. J Clin Oncol. 2005;23:[abstract 3059]
  36. Peeters M, Van Cutsem E, Hecht JR, et al. Efficacy and safety of panitumumab across five clinical studies in patients with metastatic colorectal cancer. J Clin Oncol. 2007;[Gastrointestinal cancers symposium, abstract 336]
  37. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658–1664
  38. Amado RG, Wolf M, Peeters M, et al. Wild-type Kras is required for Panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626–1634
  39. Van Cutsem E, Siena S, Humblet YS, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol. 2008;19:92–98
  40. Hecht J, Berlin J, Malik I, et al. Panitumumab therapy with IFL in metastatic colorectal cancer patients: a pharmacokinetic analysis results. J Clin Oncol. 2005;[Gastrointestinal cancers symposium, abstract 259]
  41. Berlin J, Posey J, Tchekmedyian S, et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2007;6:427–432
  42. Peeters M, Wilson G, Hotko Y, et al. Phase III study (20050181) of panitumumab with FOLFIRI compared to FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer (mCRC): preliminary safety results. J Clin Oncol. 2008;[Gastrointestinal cancers symposium, abstract 335]
  43. Douillard J, Siena S, Cassidy J, et al. Phase III study (PRIME/20050203) of panitumumab with FOLFOX4 compared to FOLFOX4 alone in patients with previously untreated metastatic colorectal cancer (mCRC): preliminary safety data results. J Clin Oncol. 2008;[Gastrointestinal cancers symposium, abstract 443]
  44. Drelich DA, Rose L, Ramirez M, Jacobs M, Mitchell E. Dermatological toxicities of panitumumab in the treatment of patients with metastatic colorectal cancer from three clinical studies. J Clin Oncol. 2007;25:[abstract 14551]
  45. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425–1433
  46. Peeters M, Van Cutsem E, Berlin J, et al. Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor, in patients with metastatic colorectal cancer across clinical trials. J Clin Oncol. 2007;25:[abstract 4138]
  47. Giusti RM, Shastri K, Pilaro AM, et al. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res. 2008;14(March (5)):1296–1302
  48. Anon. Vectibix (panitumumab) prescribing information. (v3, rev October 2007) Amgen Inc.: Thousand Oaks, CA. Available at: http://www.vectibix.com/pdfs/misc/vectibix_pi.pdf (accessed 10.03.2008).
  49. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol. 2005;22:5235–5241
  50. Berlin J, Van Cutsem E, Peeters M, et al. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer. A pooled analysis of five clinical trials. J Clin Oncol. 2007;25:[abstract 4134]
  51. Figlin RA, Belldegrun AS, Crawford J, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with advanced cancer. Phase I clinical results. J Clin Oncol. 2002;21:[abstract 35]
  52. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007;110:980–988
  53. Mitchell EP, Hercht JR, Baranda J, et al. Panitumumab activity in metastatic colorectal cancer patients with low or negative tumor epidermal growth factor receptor levels: an updated analysis. J Clin Oncol. 2007;25:[abstract 4082]
  54. Scartozzi M, Bearzi I, Berardi R, et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol. 2004;22:4772–4778
  55. Atkins D, Reiffen KA, Tegtmeier CL, et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem. 2004;52:893–901
  56. Graus-Porta D, Beerli R, Daly J, Hynes N. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalling. EMBO J. 1997;16:1647–1655
  57. Tzahar E, Waterman H, Chen X, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol. 1996;16:5276–5287
  58. Lenferink A, Pinkas-Kramarski R, van de Poll M, et al. Differential endocytic of homo- and hetero-dimeric ErbB tyrosine kinases confers signalling superiority to receptor heterodimers. EMBO J. 1998;17:3385–3397
  59. Emlet DR, Schwartz R, Brown KA, et al. HER-2 expression as a potential marker for response to therapy targeted to the EGFR. Br J Cancer. 2006;94:1144–1153
  60. Johnston S, Trudeau M, Kaufman B, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 in advanced inflammatory breast cancer with Lapatinib monotherapy. J Clin Oncol. 2008;26:1066–1072
  61. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987;327:293–297
  62. Freeman D, Amado R, Wolf M, et al. Efficacy of Panitumumab monotherapy in relation to KRAS mutational status for treating metastatic colorectal cancer from four clinical studies. J Clin Oncol. 2008;[abstract 47]
  63. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required fo response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705–5712
  64. Merlin JL, Perkins G, Lievre A, et al. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS mutation for response prediction to cetuximab in colorectal cancer. J Clin Oncol. 2008;26:[abstract 4126]
  65. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number of epidermal growth factor receptor and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6:279–286
  66. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–3995
  67. Sartore-Bianchi A, Moroni M, Veronese S, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with Panitumumab. J Clin Oncol. 2007;25:3238–3245
  68. Carcereny E, Castellvi-Bel S, Alonso V, et al. EGFR polymorphisms as predictors of clinical outcome in patients with advanced colorectal cancer treated with cetuximab and panitumumab. J Clin Oncol. 2008;26:[abstract 4124]
  69. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004;4:361–370
  70. Petit AMV, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997;151:1523–1530
  71. Ciardiello F, Bianco R, Daminao V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res. 2000;6:3739–3747
  72. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672–680
  73. Punt CJ, Tol J, Rodenburg CJ, et al. Randomized phase III study of capecitabine, oxaliplatin and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of yhe Dutch Colorectal Cancer Group. J Clin Oncol. 2008;26(Suppl.):180s;[abstract LBA 4011]
  74. Schwartzberg LS, Hurwitz H, Stephenson J, et al. Safety and pharmacokinetics of AMG706 with Panitumumab plus FOLFIRI or FOLFOX for the treatment of patients with metastatic colorectal cancer. J Clin Oncol. 2007;25:[abstract 4081]
  75. Jones HE, Goddard L, Gee JMW, et al. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocrine-Related Cancer. 2004;11:1–22
  76. Beltran PJ, Mitchell P, Moody G, et al. AMG 479, a fully human anti IGF-1 receptor antibody, inhibits P3IK/Akt signalling and exerts potent antitumor effects in combination with EGFR inhibitors in pancreatic xenograft models. J Clin Oncol. 2007;[Gastrointestinal cancers symposium, abstract 208]
  77. Sarantopoulos J, Mita AC, Mulay M, et al. A phase Ib of AMG479, a type 1 insulin-like growth factor receptor antibody in combination with Panitumumab or Gemcitabine. J Clin Oncol. 2008;26:[abstract 3583]
  78. Freeman D, Sun J, Bass R, et al. Panitumumab and cetuximab epitope mapping and in vitro activity. J Clin Oncol. 2008;26:[abstract 14536]
  79. Langerak AD, Mitchell E, Cheema G, River L, Shing M. Institutional experiences with panitumumab monotherapy in metastatic colorectal cancer patients intolerant to cetuximab. J Clin Oncol. 2007;25:[abstract 14579]
  80. Helbling D, Borner M. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol. 2007;18:963–964
  81. Asmis TR, Shah MA, Haviland D, Kemeny N. Panitumumab with or without chemotherapy on metastatic colorectal cancer: safety and unusual activity, even following progression on Cetuximab. J Clin Oncol. 2008;[Gastrointestinal cancers symposium, abstract 484]
  82. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts Cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer. 2007;97:1139–1145
  83. Scartozzi M, Bearzi I, Pierantoni C, et al. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol. 2007;25:3930–3935
  84. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230–3237
  85. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst. 2003;95:851–867
  86. Boedigiemer M, Freeman D, Fitzpatrick D, et al. Gene expression profiles can predict panitumumab monotherapy responsiveness in xenograft models: a balanced approach. Proc Amer Assoc Cancer Res. 2005;46:[abstract 1]
  87. Liotta LA, Espina V, Mehta AI, et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell. 2003;3:317–325
  88. Bencardino K, Ronzoni M, Manzoni M, et al. In vivo biological effects of Panitumumab plus chemotherapy in advanced colorectal cancer patients. J Clin Oncol. 2008;26:[abstract 14576]
  89. Hendlisz A, Marechal R, Durbecq V, et al. Modulation and prognostic value of epidermal growth factor receptor expression in circulating tumour cells during chemotherapy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:[abstract 15038]
  90. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–1765

PII: S1040-8428(09)00155-3

doi: 10.1016/j.critrevonc.2009.07.005

Critical Reviews in Oncology / Hematology
Volume 74, Issue 3 , Pages 193-202 , June 2010

Article Tools

* Image Usage & Resolution